1217 / 1311
Results
T2+ or MRS+
70
100
MRS
82
57
T2
88
57
24
Yuen JS 2004
T2 + MRS
80
80
Review
Müller-Lisse U 2003
dyn. MRI, central
87
68
dyn. MRI, peripheral
74
87
111
Ito H 2003
MRS
75
63
T2
41 - 61
77 - 81
52
Scheidler J 1999
Method
Spec [%]
Sens [%]
n
Author
Prostate carcinoma: T2
Prostate carcinoma: DCE-MRI
Prostate carcinoma: DWI
Grosu A, Strahlenther Onkol 2005
FDG-PET
•
T-Staging: Detection
•
Sensitivity localized disease 67%
advanced disease92%
•
Limitations
–
Low glucose uptake
–
Large overlap between tumor and benign
hyperplasia
–
Renal excretion of FDG into the bladder
Choline PET
•
Better than FDG-PET
•
Still overlap between tumor and benign
hyperplasia
•
N-Staging
–
Sensitivity 80%,
–
Specificity 96%
–
CT+MRI: Sensitivity 47%, specificity 98%